

Express Mail No. EV 346 812 675 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Nurit LIVNAH et al.

Confirmation No. 9174

Application No.: 10/764,288

Group Art Unit: 1614

Filing Date: January 23, 2004

Examiner:

For: PROTEIN KINASE INHIBITORS  
COMPRISING ATP MIMETICS CONJUGATED  
TO PEPTIDES OR PEPTIDOMIMETICS

Atty. Docket No.: 87534-4300

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

Sir:

Pursuant to applicants' duty of disclosure under 37 C.F.R. 1.56, enclosed are copies of eighteen (18) references for the Examiner's review and consideration. These references are listed on the enclosed Form PTO-1449. It is respectfully requested that these references be made of record in this application by the Examiner's completion and return of the PTO Form 1449.

No fee is believed to be due for the filing of this statement as it is being submitted prior to an initial office action for this application. Should any fees be required, however, please charge such fees to **Winston & Strawn LLP** Deposit Account No. 50-1814.

Respectfully submitted,

Date: 25 FEBRUARY 2005


Stephen Filipik (Reg. No. 33,384)

for: Allan A. Fanucci (Reg. No. 30,256)

**WINSTON & STRAWN LLP**  
**CUSTOMER NO. 28765**  
(212) 294-3311

Enclosure

NY:901345.2



<b>LIST OF REFERENCES CITED BY APPLICANT</b> <i>(Use several sheets if necessary)</i>				ATTY. DOCKET NO.: <b>87534-4300</b>		APPLICATION NO.: <b>10/764,288</b>	
				APPLICANT: <b>Nurit LIVNAH et al.</b>			
				FILING DATE: <b>January 23, 2004</b>		GROUP: <b>1614</b>	
<b>U.S. PATENT DOCUMENTS</b>							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA						
	AB						
	AC						
<b>FOREIGN PATENT DOCUMENTS</b>							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
	AD						
	AE						
<b>OTHER REFERENCES</b> <i>(Including Author, Title, Date, Pertinent Pages, Etc.)</i>							
	AF	Dario R. Alessi et al., "Molecular basis for the substrate specificity of protein kinase B; comparison with MAPKAP kinase-1 and p70 S6 kinase," <i>FEBS Letters</i> 399, pp. 333-338 (1996)					
	AG	Yi Fang et al., "Focal adhesion kinase affects the sensitivity of human hepatocellular carcinoma cell line SMMC-7721 to tumor necrosis factor- $\alpha$ /cycloheximide-induced apoptosis by regulating protein kinase B levels," <i>Eur. J. Biochem</i> , vol. 268, pp. 4513-4519 (2001)					
	AH	Hiroyoshi Hidaka et al, "Isoquinolinesulfonamides, Novel and Potent Inhibitors of Cyclic Nucleotide Dependent Protein Kinase and Protein Kinase C," <i>Biochemistry</i> , vol. 23, pp. 5036-5041 (1984)					
	AI	Chandra C. Kumar et al., "Expression, purification, characterization and homology modeling of active Akt/PKB, a key enzyme involved in cell survival signaling," <i>Biochimica et Biophysica Acta</i> , vol. 1526, pp. 257-268 (2001)					
	AJ	Ai-xue Liu et al., "AKT2, a Member of the Protein Kinase B Family, Is Activated by Growth Factors, v-Ha-ras, and v-src through Phosphatidylinositol 3-Kinase in Hunan Ovarian Epithelial Cancer Cells," <i>Cancer Research</i> , vol. 58, pp. 2973-2977 (1998)					
	AK	Mart Loog et al., "Adenosine-5'-Carboxylic Acid Peptidyl Derivatives as Inhibitors of Protein Kinases," <i>Bioorganic &amp; Medicinal Chemistry Letters</i> , vol. 9, pp. 1447-1452 (1999)					
	AL	Robert Martell et al., "Effects of Protein Kinase Inhibitors 1(5-Isoquinolinesulfonyl)-2-Methylpiperazine Dihydrochloride (H-7) and N-[2-Guanidinoethyl]-5-Isoquinolinesulfonamide Hydrochloride (HA1004) on Calcitriol-Induced Differentiation of HL-60 Cells," <i>Biochemical Pharmacology</i> , vol. 37, pp. 635-640 (1988)					
	AM	Karleen Nicholson et al., "The protein kinase B/Akt signalling pathway in human malignancy," <i>Cellular Signalling</i> , vol. 14, pp. 381-395 (2002)					

	AN	Masakatsu Nishikawa et al., "1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine(H-7), A Potent Inhibitor of Protein Kinases, Inhibits the Differentiation of HL-60 Cells Induced by horbol Diester", <i>Life Sciences</i> , vol. 39, pp. 1101-1107 (1986)
	AO	Toshiyuki Obata et al., "Peptide and Protein Library Screening Defines Optimal Substrate Motifs for AKT/PKB*," <i>The Journal of Biological Chemistry</i> , vol. 275, no. 46, pp. 36108-36115 (2000)
	AP	Keykavous Parang et al., "Mechanism-based design of a protein kinase inhibitor," <i>Nature Structure Biology</i> , vol. 8, number 1, pp. 37-41 (2001)
	AQ	G. Perez-Tenorio et al., "Activation of AKT/PKB in breast cancer predicts a worse outcome among endocrine treated patients," <i>British Journal of Cancer</i> , vol. 86, pp. 540-545 (2002)
	AR	Ricouart et al., "Design of Potent Protein Kinase Inhibitors Using the Bisubstrate Approach," <i>J. Med. Chem.</i> , vol. 34, pp. 73-78 (1991)
	AS	Baljinder Salh et al., "Dysregulation of Phosphatidylinositol 3-Kinase and Downstream Effectors in Human Breast Cancer," <i>Int. J. Cancer</i> , vol. 98, pp. 148-154 (2002)
	AT	Martin Schlitzer et al., "Design, Synthesis and Early Structure - Activity Relationship of Farnesyltransferase Inhibitors Which Mimic Both the Peptidic and the Prenylic Substrate," <i>Biorganic &amp; Medicinal Chemistry</i> , vol. 8, pp. 1991-2006 (2000)
	AU	Shuho Semba et al., "The in Vitro and in Vivo Effects of 2-(4-Morpholinyl)-8-phenylchromone (LY294002), a Specific Inhibitor of Phosphatidylinositol 3'-Kinase, in Human Colon Cancer Cells," <i>Clinical Cancer Research</i> , vol. 8, pp. 1957-1963 (2002)
	AV	V. Waldmann et al., "Absence of mutations in the pleckstrin homology (PH) domain of protein kinase B (PKB/Akt) in malignant melanoma" <i>Melanoma Research</i> , vol. 12, pp. 45-50 (2002)
	AW	Michael J. Zinda et al., "AKT-1, -2, and -3 are Expressed in Both Normal and Tumor Tissues of the Lung, Breast, Prostate, and Colon," <i>Clinical Cancer Research</i> , vol. 7, pp. 2475-2479 (2001)
<b>EXAMINER</b>		<b>DATE CONSIDERED</b>